Email this article INTRACELLULAR GEMCITABINE MONOPHOSPHATE LEVELS PREDICT CHEMOTHERAPY EFFICACY IN GEMCITABINE-TREATED PATIENTS WITH BLADDER CANCER
- Authors: Yanova M.R.1, Zhiyanov A.P.1, Antipenko I.D.1, Slobodov S.A.1, Stepanova E.V.1
-
Affiliations:
- NIU Higher School of Economics, Faculty of Biology and Biotechnology
- Issue: Vol 513, No 1 (2023)
- Pages: 581-585
- Section: Articles
- URL: https://journals.rcsi.science/2686-7389/article/view/244389
- DOI: https://doi.org/10.31857/S2686738923600140
- EDN: https://elibrary.ru/GUAXOE
- ID: 244389
Cite item
Open Access
Access granted
Subscription Access
Abstract
Gemcitabine monophosphate (dFdCMP), one of the intracellular forms of phosphorylated gemcitabine, determines its antitumor activity. A pharmaco-molecular model for determining gemcitabine relative monophosphate levels has been developed based on the assessment of the activity of ENT1, ENT2 channels and dCK, CDA enzymes in tumor tissue. Gemcitabine relative monophosphate levels is a more relevant predictive factor of gemcitabine resistance of bladder cancer when compared with the expression of individual markers related to dFdCMP formation.
Keywords
About the authors
M. R. Yanova
NIU Higher School of Economics, Faculty of Biology and Biotechnology
Author for correspondence.
Email: myanova@hse.ru
Russian Federation, Moscow
A. P. Zhiyanov
NIU Higher School of Economics, Faculty of Biology and Biotechnology
Email: myanova@hse.ru
Russian Federation, Moscow
I. D. Antipenko
NIU Higher School of Economics, Faculty of Biology and Biotechnology
Email: myanova@hse.ru
Russian Federation, Moscow
S. A. Slobodov
NIU Higher School of Economics, Faculty of Biology and Biotechnology
Email: myanova@hse.ru
Russian Federation, Moscow
E. V. Stepanova
NIU Higher School of Economics, Faculty of Biology and Biotechnology
Email: myanova@hse.ru
Russian Federation, Moscow
References
- Lenis A. T., Lec P. M., and Chamie K., Bladder cancer a review, JAMA – Journal of the American Medical Association, vol. 324, no. 19. American Medical Association, pp. 1980–1991, Nov. 17, 2020.
- Карпин А.Д., Старинский В.В., and Шахзадова А.О., Состояние онкологической помощи населению России в 2020 году, 2021.
- Cao Y. et al., Phase I study of gemcitabine-cisplatin versus pemetrexed-cisplatin for patients with advanced or metastatic bladder cancer, JBUON, vol. 23, no. 2, pp. 475–481, 2018.
- Saiki Y., Hirota S., and Horii A., Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance, Cancer Drug Resistance, vol. 3, no. 4. OAE Publishing Inc., pp. 819–831, 2020.
- Wong A., Soo R.A., Yong W.P., and Innocenti F., Clinical pharmacology and pharmacogenetics of gemcitabine, Drug Metabolism Reviews, vol. 41, no. 2. pp. 77–88, May 2009.
- Pastor-Anglada M. and Pérez-Torras S., Emerging roles of nucleoside transporters, Frontiers in Pharmacology, vol. 9, no. JUN. Frontiers Media S.A., Jun. 06, 2018.
- Spratlin J. et al., The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma. Accessed: Dec. 12, 2022. [Online]. Available.
- Nishio R. et al., Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCMP), Cancer Sci, vol. 102, no. 3, pp. 622–629, Mar. 2011.
- Yang H. et al., Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer, Cancers (Basel), vol. 14, no. 13, Jul. 2022.
- Espinoza J.A. et al., Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients, Histopathology, vol. 68, no. 5, pp. 722–728, Apr. 2016.
- Ioannidis G. et al., Messenger-RNA expression of five gemcitabine sensitivity-related genes predicting outcome in advanced-stage non-small cell lung cancer, Anticancer Res, vol. 40, no. 2, pp. 901–913, 2020.
- Hoadley K.A. et al., Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer, vol. 173, no. 2, pp. 291–304, 2020.
- Garcia-Cremades M., Melillo N., Troconiz I.F., and Magni P., Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer, Clin Transl Sci, vol. 13, no. 3, pp. 608–617, May 2020.
- Virtanen P. et al., SciPy 1.0: fundamental algorithms for scientific computing in Python, Nat Methods 17, 261–272 (2020).
- Mackey J. R. et al., Gemcitabine Transport in Xenopus Oocytes Expressing Recombinant Plasma Membrane Mammalian Nucleoside Transporters. [Online]. Available.
- Garcia-Cremades M. et al., Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer, European Journal of Pharmaceutical Sciences, vol. 115.
- Derissen E. J. B. et al., Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides, Br J Clin Pharmacol, 84: 1279–1289, 2018.
Supplementary files
